Abstract
Severe and difficult-to-treat asthma patients have impaired health status and account for over half of the cost of the disease and probably all of its mortality. Guideline-based treatment for these refractory asthma patients includes high doses of inhaled steroids and long acting beta2-agonists (LABA) as well as additional medication such as theophylline, oral steroids and leukotriene-antagonists. However, management regimens are rarely successful in these patients, the treating physicians are often at a loss and there are still many areas of uncertainty regarding steroid-responsiveness, safety issues and maximal dosing of inhaled corticosteroids (ICS) and bronchodilators and possible differences between ICS preparations. Furthermore, there are many other classes of medication that have been or are currently tested in severe asthma: Anti - Immunoglobulin E (IgE) seems to have a good clinical effect while results on anti - Interleukin 5 (IL-5) are less promising and anti - tumor necrosis factor alpha (TNFα) treatment is currently being tested in controlled studies. Other steroid sparing drugs (cyclosporine, tacrolimus, methotrexate, gold) have been used but results are unsatisfactory and side-effects are notable so steroids remain the cornerstone of severe asthma treatment. The addition of macrolides is beneficial in many cases and this is in step with the evidence of chronic chlamydia infection in severe asthma. Although there are case reports supporting the use of Immunoglobulin G (IgG), there are no controlled studies supporting this type of treatment. In this report, the authors review the various issues of guideline based therapy but also new approaches that include anti-IgE antibodies, anti-cytokines (anti-IL-5, anti-IL9, anti-TNF).
Keywords: Severe asthma, management, ICS, LABA, leukotriene antagonists, anti-IgE, anti-TNFα
Current Medicinal Chemistry
Title: Evaluation and Management of Severe Asthma
Volume: 14 Issue: 9
Author(s): Mina Gaga, Eleftherios Zervas, Spiros Grivas, Mario Castro and Pascal Chanez
Affiliation:
Keywords: Severe asthma, management, ICS, LABA, leukotriene antagonists, anti-IgE, anti-TNFα
Abstract: Severe and difficult-to-treat asthma patients have impaired health status and account for over half of the cost of the disease and probably all of its mortality. Guideline-based treatment for these refractory asthma patients includes high doses of inhaled steroids and long acting beta2-agonists (LABA) as well as additional medication such as theophylline, oral steroids and leukotriene-antagonists. However, management regimens are rarely successful in these patients, the treating physicians are often at a loss and there are still many areas of uncertainty regarding steroid-responsiveness, safety issues and maximal dosing of inhaled corticosteroids (ICS) and bronchodilators and possible differences between ICS preparations. Furthermore, there are many other classes of medication that have been or are currently tested in severe asthma: Anti - Immunoglobulin E (IgE) seems to have a good clinical effect while results on anti - Interleukin 5 (IL-5) are less promising and anti - tumor necrosis factor alpha (TNFα) treatment is currently being tested in controlled studies. Other steroid sparing drugs (cyclosporine, tacrolimus, methotrexate, gold) have been used but results are unsatisfactory and side-effects are notable so steroids remain the cornerstone of severe asthma treatment. The addition of macrolides is beneficial in many cases and this is in step with the evidence of chronic chlamydia infection in severe asthma. Although there are case reports supporting the use of Immunoglobulin G (IgG), there are no controlled studies supporting this type of treatment. In this report, the authors review the various issues of guideline based therapy but also new approaches that include anti-IgE antibodies, anti-cytokines (anti-IL-5, anti-IL9, anti-TNF).
Export Options
About this article
Cite this article as:
Gaga Mina, Zervas Eleftherios, Grivas Spiros, Castro Mario and Chanez Pascal, Evaluation and Management of Severe Asthma, Current Medicinal Chemistry 2007; 14 (9) . https://dx.doi.org/10.2174/092986707780362961
DOI https://dx.doi.org/10.2174/092986707780362961 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the Treatment of Chronic Inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Drug Repositioning Through Network Pharmacology
Current Topics in Medicinal Chemistry Small Molecule Inhibitors of Phosphoinositide 3-Kinase (PI3K) δ and γ
Current Topics in Medicinal Chemistry Long-term Exposure to Cadmium in Food and Cigarette Smoke, Liver Effects and Hepatocellular Carcinoma
Current Drug Metabolism Multi-targeting Andrographolide and its Natural Analogs as Potential Therapeutic Agents
Current Topics in Medicinal Chemistry Mechanism of Action of Methamphetamine within the Catecholamine and Serotonin Areas of the Central Nervous System
Current Drug Abuse Reviews Gene Expression Profiling as a Tool for Positional Cloning of Genes- Shortcut or the Longest Way Round
Current Genomics Inhibition of IκB Phosphorylation by a Novel IKK Inhibitor IMD-1041 Attenuates Myocardial Dysfunction After Infarction
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Evaluation of Subcutaneous and Visceral Adipose Tissue Changes by Computed Tomography in Coronavirus Disease 2019 and Comparison with Quantitative Analysis of Lung Involvement
Current Medical Imaging A New Threat to Mankind: COVID 19 - All You Need to Know
Coronaviruses The Human Pseudoautosomal Region (PAR): Origin, Function and Future
Current Genomics Saccharomyces cerevisiae as a Model for Screening the Effects of Volatile Organic Compounds
Current Biotechnology Systems Biology Approaches and Metabolomics for Understanding Japanese Traditional Kampo Medicine
Current Pharmacogenomics and Personalized Medicine Inhalable Antibiotic Nanoformulations for the Treatment of Pseudomonas Aeruginosa Infection in Cystic Fibrosis – A Review
Drug Delivery Letters Atrial Fibrillation with a Focus on Oral Antiarrhythmic Therapy
Current Drug Therapy Bacterial Conjunctivitis in Childhood: Etiology, Clinical Manifestations, Diagnosis, and Management
Recent Patents on Inflammation & Allergy Drug Discovery Determination of Interchangeability of Different Brands of Diclofenac Sodium Sustained Release Tablets in Healthy Subjects Using Pharmacokinetic End Points
Letters in Drug Design & Discovery Preclinical Evidence for the Pharmacological Actions of Glycyrrhizic Acid: A Comprehensive Review
Current Drug Metabolism The Applications of Biomarkers in Early Clinical Drug Development to Improve Decision-Making Processes
Current Clinical Pharmacology IgE-Binding Epitope Analysis of Bla g 5, the German Cockroach Allergen
Protein & Peptide Letters Antiproliferative Properties of Extracts from <i>Stachys sieboldii</i> MIQ
Current Bioactive Compounds